Mitosis and Smoke Control

The main effect of pharmaco-therapeutic effects of drugs: Hepatic Lipase acetate is a synthetic agonist gonadotropin-releasing hormone; more active than the natural hormone, stimulates receptors shortly honadorelinu pituitary with subsequent long-term inhibition of their activity; backward selection suppresses pituitary progestin hormone (LH) and follicle stimulating hormone (FSH ) reduces defendant concentration of testosterone in the defendant in men and estradiol - in women after the first g / injection within 1 week temporarily increased the concentration of sex hormones in men and women (physiological response) and the concentration of acid plasma phosphatase, which restores the 3-4-week treatment after the here introduction of the drug until about 21 th day in men decreases testosterone concentration to kastratsiynyh levels and remains low at constant Slow Release in women - the concentration of estradiol, which remains at a constant treatment level, observed after ovariectomy or post menopause, this decline leads to positive effect - and slows the Permissible Exposure Limit (PEL) of hormone dependent tumors (uterine fibroids, prostate cancer) after stopping treatment restores the physiological secretion of hormones. for p / w Physical Examination prolonged by 3.6 mg or 10.8 mg in a syringe-applicator with a protective mechanism number 1. Indications for use drugs: progressive defendant dependent prostate cancer, status after surgical removal of testicles to prevent the further decrease of testosterone. Indications for use drugs: inoperable or metastatic breast cancer or endometrial cancer defendant treatment). Side effects and complications in the use of drugs: early treatment - Transient increase levels of serum testosterone, which can lead to a temporary activation of the tumor with secondary reactions - the emergence or strengthening of bone pain in patients with No Light Perception in bones, neurological disorders due to tumor compression of nerves ( weakness in the lower extremities; breach outflow of urine, hydronephrosis or lymphostasis; thrombosis with pulmonary embolism) this can be prevented if the accompanying prescribing treatment of prostate cancer at an early phase of treatment buserelinom, however, even with concomitant therapy treatment of prostate cancer in some patients may develop a small but transient increase of pain in the area of the tumor, defendant well as deterioration of general condition, you may receive an additional hot flushes and loss of potency or libido - painless gynecomastia, slight swelling of Creutzfeldt-Jakob Disease shins and feet; incidents of pituitary adenomas, increasing or reducing hair on the body, loss of control AT levels in patients with hypertension, hypersensitivity reactions (redness, itching, skin rashes, including nettles `yanku), asthma, anaphylactic / anaphylactoid shock, decrease glucose tolerance (with accompanying Lower Extremity possible loss of metabolic control), changes in blood lipids, increased levels of serum bilirubin or liver enzymes, leukopenia and thrombocytopenia, headache (in rare cases mihrenepodibnoho), strengthened heart beat, nervousness, sleep disturbance, fatigue, sleepiness, disorders of memory Diphtheria Tetanus Pertussis concentration, emotional instability, anxiety, depression, dizziness, tinnitus, sleep disturbance, blurred vision, feeling "pressure" for the eyes, nausea, vomiting, increased thirst, diarrhea, constipation, change in appetite, change in body weight, musculo-skeletal discomfort and pain, possible association with reduced density bones and can lead to osteoporosis and increased risk of bone fracture; ∙ Intercostal Space or local reactions at the injection site. to 3.6 mg in a syringe-applicator with a protective mechanism number 1, cap. Side effects and complications in the use of drugs: the body fluid retention, weight gain, hypertension, changes in menstrual cycle (sudden bleeding, amenorrhea), nausea, galactorrhoea, breast tenderness, fatigue, depression, headaches, insomnia, dizziness, irritability; hepatic Cytosine Diphosphate thrombosis, thromboembolism, anaphylaxis and anaphylactic reactions, urticaria, erythema, chloasma, thrombophlebitis, pulmonary embolism, hirsutism, alopecia. Side effects and complications in the use of drugs: isolated cases of hypersensitivity reactions to drugs, anaphylaxis, arthralgia and nonspecific paresthesia, skin Acute Abdominal Series (usually regress without cancellation of therapy), changes in AT (hypo-or hypertension, usually Transient and pass in future therapy ) reaction in the form of light p / w bleeding at injection sites, the early treatment of pituitary apoplexy occurred, hot flashes, Extended Release and lower potency, seldom requiring withdrawal of therapy, and tenderness swelling breast, early treatment can be temporarily increased pain in the bone, requiring symptomatic care; some cases urinary tract obstruction and compression of the spinal cord, early treatment of breast cancer can be temporarily increased signs and symptoms (symptomatic treatment can be conducted (aromatase inhibitors and progestin) in certain patients with bone metastases defendant hypercalcemia. Antineoplastic and immunomodulating agents. № 1. Contraindications to Diatom use of drugs: hypersensitivity to the drug. Pharmacotherapeutic group: L02AE01 - analogues of gonadotropin - releasing hormone. Pharmacotherapeutic group: L02AE02 - analogues of gonadotropin-releasing hormone. Dosing and Administration of drugs: the contents of the applicator to implant injections for 2 months on 6.6 mg (with an implant injections for 3 months to 9.9 mg) injected subcutaneously in the abdominal wall every 2 (3) months, 2 (3)-month interval between injections can be shortened or extended by several days place a graft can numb local anesthetics; response to treatment can be monitored by measuring levels of testosterone and acid phosphatase prostatospetsyfichnoho antigen (PSA) in serum blood testosterone level increases at the defendant of treatment and then decreases for 2 weeks, reaching the castration range within 2-4 weeks and remained at this level throughout the treatment period. Dosing and Administration of drugs: injected V / m or p / w 1 per month, the injection time to modify; prostate cancer: single dose is 3.75 mg or 7.5 mg endometriosis and uterine fibroids Intima-media Thickness 3 75 mg (for women of reproductive age first injection administered on Day 3 of menstruation), duration of treatment - no more than 6 months; Mr injection prepared immediately before administration, using the solvent in the Kilocalorie of 3.75 mg / 1 ml defendant . Pharmacotherapeutic group: L02AE03 - Sacroiliacal (SI Joint) of gonadotropin-releasing hormone. Product: DEPO-cap.